Go Pro
→ Ticker Revealed: Pre-IPO Access to 'Next Elon Musk' Company (From Banyan Hill Publishing) (Ad)tc pixel Free SCTX Stock Alerts

Scribe Therapeutics (SCTX) Stock Forecast & Price Target

Scribe Therapeutics logo
$32.83 +1.78 (+5.73%)
As of 08/20/2026 04:00 PM Eastern

Scribe Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Buy
Based on 3 Analyst Ratings
Sell
0
Hold
0
Buy
3

Based on 3 Wall Street analysts who have issued ratings for Scribe Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 3 analysts, 3 have given a buy rating for SCTX.

Consensus Price Target

$49.00
49.25% Upside
According to the 3 analysts' twelve-month price targets for Scribe Therapeutics, the average price target is $49.00. The highest price target for SCTX is $60.00, while the lowest price target for SCTX is $37.00. The average price target represents a forecasted upside of 49.25% from the current price of $32.83.
MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
Get the Latest News and Ratings for SCTX and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Scribe Therapeutics and its competitors.

Sign Up
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SCTX Analyst Ratings Over Time

TypeCurrent Forecast
8/21/25 to 8/21/26		1 Month Ago
7/22/25 to 7/22/26		3 Months Ago
5/23/25 to 5/23/26		1 Year Ago
8/21/24 to 8/21/25
Strong Buy
0 Strong Buy rating(s)
 N/A N/A N/A
Buy
3 Buy rating(s)
 N/A N/A N/A
Hold
0 Hold rating(s)
 N/A N/A N/A
Sell
0 Sell rating(s)
 N/A N/A N/A
Consensus Price Target$49.00N/AN/AN/A
Forecasted Upside49.25% UpsideN/AN/AN/A
Consensus RatingBuyN/AN/AN/A

SCTX Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

SCTX Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Scribe Therapeutics Stock vs. The Competition

TypeScribe Therapeutics CompaniesBroader Market
Consensus Rating Score
3.00
1.63
2.53
Consensus RatingBuyReduceModerate Buy
Predicted Upside49.25% Upside170.56% Upside12.99% Upside
News Sentiment Rating
Neutral News

See Recent SCTX News
Positive News
Positive News
Export
DateBrokerageAnalystActionRatingPrice TargetReport Date
Upside/Downside		Details
8/18/2026
Guggenheim logo
Guggenheim
5 of 5 stars
Debjit Chattopadhyay
Debjit Chattopadhyay
5 of 5 stars
Initiated CoverageBuy$50.00+135.96%
8/18/2026
Wells Fargo & Company logo
Wells Fargo & Company
3 of 5 stars
Yanan Zhu
3 of 5 stars
Initiated CoverageOverweight$60.00+183.15%
8/18/2026
Leerink Partners logo
Leerink Partners
2 of 5 stars
David Risinger
David Risinger
Not Rated
Initiated CoverageOutperform$37.00+74.61%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 05:10 AM ET.


SCTX Forecast - Frequently Asked Questions

According to the research reports of 3 Wall Street equities research analysts, the average twelve-month stock price forecast for Scribe Therapeutics is $49.00, with a high forecast of $60.00 and a low forecast of $37.00.

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Scribe Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCTX shares.

According to analysts, Scribe Therapeutics's stock has a predicted upside of 49.25% based on their 12-month stock forecasts.

Scribe Therapeutics has been rated by research analysts at Guggenheim, Leerink Partners, and Wells Fargo & Company in the past 90 days.

Analysts like Scribe Therapeutics more than other "" companies. The consensus rating for Scribe Therapeutics is Buy while the average consensus rating for "" companies is Reduce. Learn more on how SCTX compares to other companies.

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Scribe Therapeutics Recommendations


This page (NASDAQ:SCTX) was last updated on 8/21/2026 by MarketBeat.com Staff.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
They didn't warn anyone in 1971. This time someone is warning you.
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel
Buy this stock today
Marc Chaikin, founder of Chaikin Analytics, is sharing a strategy he calls 'Sell This, Buy That' - a way to mo...
Chaikin Analytics | Sponsoredtc pixel